Comparing Malaria Treatments in Madagascar
Author Information
Author(s): Didier Ménard, Nina Harimanana, Ramiandrasoa Zakaherizo, Arthur Randriamanantena, Noéline Rasoarilalao, Martial Jahevitra, Arsène Ratsimbasoa, Luciano Tuseo, Andrianirina Raveloson
Primary Institution: Institut Pasteur de Madagascar
Hypothesis
Is the combination therapy of amodiaquine plus sulphadoxine-pyrimethamine (AQ+SP) as effective as artemisinin-based combination therapy (AQ+AS) for treating uncomplicated falciparum malaria in Madagascar?
Conclusion
The study found that AQ+SP is as effective as AQ+AS for treating uncomplicated malaria in Madagascar.
Supporting Evidence
- All treatment regimens, except for chloroquine, had clinical cure rates above 97% by day-14.
- AQ+SP was found to be as effective as AQ+AS.
- The risk of new infection was higher for AQ+AS compared to AQ+SP.
Takeaway
This study looked at two different treatments for malaria in kids and found that a cheaper option works just as well as the more expensive one.
Methodology
The study was a randomized clinical trial involving 287 children aged 6 months to 15 years with uncomplicated falciparum malaria, comparing the efficacy of different treatment regimens.
Potential Biases
Potential bias in treatment assignment and follow-up due to the nature of the study design.
Limitations
The study was limited to children and may not be generalizable to adults.
Participant Demographics
Children aged 6 months to 15 years with uncomplicated falciparum malaria.
Statistical Information
P-Value
p<0.05
Confidence Interval
95% CI, 50.5–307.9
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website